TIRZEPATIDE 30mg Per Vial
TIRZEPATIDE 30mg Per Vial
Bacteriostatic (BAC) Water Included
No separate purchase required
Tirzepatide is backed by one of the largest clinical research programmes of any investigational metabolic peptide - with dual GIP and GLP-1 receptor activity at its core.
What is Tirzepatide?
Tirzepatide is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it one of the most extensively studied dual-incretin compounds in modern metabolic research. Its ability to influence two complementary incretin pathways has generated significant research into glucose regulation, insulin secretion, appetite, energy intake and body-weight regulation.
Understanding the Two Pathways
GIP and GLP-1 are naturally occurring hormones released in response to nutrients. Although both influence insulin secretion, they also have distinct biological roles. Tirzepatide allows researchers to investigate how these two pathways interact when activated together.
Tirzepatide & GLP-1
GLP-1 plays an important role in maintaining glucose homeostasis. GLP-1 receptor signalling is associated with glucose-dependent insulin secretion, regulation of glucagon and gastrointestinal signalling, as well as pathways involved in appetite and food intake.
Tirzepatide & GIP
GIP contributes to nutrient-stimulated insulin secretion and has additional effects on adipose and metabolic tissues. The combination of GIP and GLP-1 signalling is particularly interesting because the two pathways may produce complementary metabolic effects.
Tirzepatide & Glucose Research
Tirzepatide has been extensively evaluated in human clinical trials. It is an FDA-approved pharmaceutical active ingredient, with Mounjaro approved for improving glycaemic control in adults with type 2 diabetes and Zepbound approved for chronic weight management in certain adults with obesity or overweight.
Tirzepatide & Body-Weight Research
Clinical research has also investigated tirzepatide extensively in adults with overweight or obesity. Research has demonstrated substantial reductions in body weight compared with placebo, alongside broader metabolic changes.
Areas Researchers Continue to Investigate
- GLP-1 signalling
- GIP signalling
- Glucose homeostasis
- Insulin sensitivity
- Appetite and energy intake
- Body composition
- Lipid metabolism
- Metabolic health
What makes Tirzepatide different?
-
Dual-receptor activity — Targets both GIP and GLP-1 receptors.
-
Extensive clinical research — Supported by a large body of human clinical data.
-
Metabolic signalling — Influences several pathways involved in glucose and energy regulation.
- Body-composition research — Extensively studied in populations with diabetes, overweight and obesity.
Research Areas at a Glance
GLP-1 Signalling • GIP Signalling • Glucose Homeostasis • Insulin Sensitivity • Appetite Research • Body Composition • Metabolic Research
Research Disclaimer: Tirzepatide is an established pharmaceutical compound with approved medical applications in specific jurisdictions and indications; however, the Peptigen product is supplied exclusively for laboratory research purposes. Information provided on this website is for scientific and educational purposes and should not be considered medical advice, a treatment recommendation, or guidance for personal use. Peptigen does not provide dosing, administration or reconstitution guidance for research compounds. Purchasers are responsible for ensuring that research materials are handled within an appropriate research environment and in accordance with applicable laws, regulations, laboratory protocols and safety requirements. Research use only.
Peptigen.
Quality. Research. Potential.